Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

BioNTech SE

Moderna

It had much to do with a certain Greek letter.

Why Some Coronavirus Stocks Plunged Today

In what should have been good news for the stock, Novavax Inc (NASDAQ: NVAX) is down over 6% on the day on heavy volumes with over 10 million shares traded (double the 10 day average) and over 57,000 options traded. This is in spite of the fact the stock received conditional approval in Europe for its COVID-19 vaccine.

Novavax Shares Fall On Heavy Options Volume Following COVID Vaccine Approval By EU

The European Commission has granted conditional marketing authorization to Novavax Inc's (NASDAQ: NVAX) Nuvaxovid COVID-19 Vaccine for active immunization to prevent COVID-19 in individuals 18 years of age & older.  The authorization follows the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommendation today to authorize the vaccine.

Novavax's COVID-19 Vaccine Scores Conditional Approval In Europe

Pfizer

Vaccine stocks aren't enjoying a good morning today, but there's plenty of reason to suspect that they are in for a better year in 2022. The post MRNA, NVAX, OCGN, PFE, BNTX: What Is Going on With Vaccine Stocks Today?

MRNA, NVAX, OCGN, PFE, BNTX: What Is Going on With Vaccine Stocks Today?

- Nuvaxovid™ COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]) listed for emergency use by the WHO - EUL for Nuvaxovid complements listing for Novavax vaccine manufactured and marketed by Serum Institute of India as Covovax™ - EUL by WHO is a prerequisite for exports to numerous countries participating in the COVAX Facility GAITHERSBURG, Md., Dec. 20, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the World Health Organization (WHO) has granted a second Emergency Use Listing (EUL) for NVX-CoV2373, Novavax' recombinant protein nanoparticle COVID-19 vaccine with Matrix-M™ adjuvant, for the prevention of COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

World Health Organization Grants Second Emergency Use Listing for Novavax COVID-19 Vaccine

Novavax's (NVAX) COVID-19 vaccine gets approval from WHO for emergency use listing. The vaccine is now pre-qualified for supply to numerous countries participating through the COVAX facility.

Novavax (NVAX) COVID Jab Gets WHO Nod for Emergency Use Listing

Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) is the first protein-based COVID-19 vaccine authorized for use in Europe Novavax and the European Commission previously announced an advance purchase agreement for up to 200 million doses through 2023 Authorization follows positive recommendation by European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) GAITHERSBURG, Md., Dec. 20, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Commission (EC) has granted Novavax conditional marketing authorization (CMA) for Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

European Commission Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine

If confirmed by the EU's executive commission, the Novavax shot will become the fifth option for Europeans looking to get the jab.

Novavax Covid-19 Vaccine Wins Approval From European Union Regulator

Novavax Inc (NASDAQ: NVAX) is expected to start delivering its COVID-19 vaccines to the European Union in Q1 of 2022, Reuters reported citing an EU source. The drug regulator met on Monday to decide whether to approve the shot.

Novavax To Possibly Kickstart COVID-19 Vaccine Delivery To EU In Q1 2022: Source

A new strategy that focuses on international markets for its Covid-19 vaccine appears to be paying off for U.S. drug maker Novavax. The post NVAX Stock Alert: 2 Big Reasons Novavax Is Shooting Higher Today appeared first on InvestorPlace.

NVAX Stock Alert: 2 Big Reasons Novavax Is Shooting Higher Today

The two-dose protein-based vaccine, branded Nuvaxovid, is the fifth coronavirus vaccine recommended by the EU.

Novavax Climbs as Its Covid Vaccine Recommended for EU Approval

The European Medicines Agency, the regulator for the European Union, has recommended granting a conditional marketing authorization to the COVID-19 vaccine developed by Novavax Inc. NVAX, +11.49% to prevent the illness in people aged 18 and older. The vaccine called Nufaxovid is now the fifth recommended in the EU for preventing COVID.

EU regulator backs authorization for Novavax COVID-19 vaccine, sending stock up 10% premarket

European Commission decision on conditional marketing authorization expected imminently Upon authorization, Nuvaxovid™ (also known as NVX-CoV2373) will be the first protein-based COVID-19 vaccine available in Europe GAITHERSBURG, Md., Dec. 20, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Medicines Agency (EMA) has recommended granting a conditional marketing authorization for Novavax' COVID-19 vaccine (also known as NVX-CoV2373) to prevent COVID-19 in people from 18 years of age and older.

Novavax Receives Positive European Medicines Agency Recommendation for Conditional Marketing Authorization of its COVID-19 Vaccine

The stock price of Novavax, Inc. (NASDAQ: NVAX) increased by over 9% pre-market today. This is why it happened.

Novavax Stock (NVAX): Why The Price Jumped Today

New York, New York--(Newsfile Corp. - December 18, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Novavax, Inc. (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the "Class Period"), of the important January 11, 2022 lead plaintiff deadline.SO WHAT: If you purchased Novavax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...

Rosen, A Leading Law Firm, Encourages Novavax, Inc. Investors with Losses to Secure Counsel Before Important January 11 Deadline in Securities Class Action - NVAX

Zoom Video

Zoom and Novavax remain well below their pandemic-era peaks.

Is the Omicron Surge Helping These 2 Nasdaq Stocks Recover?

The World Health Organization issued an emergency use listing to Covovax, Serum Institute of India's version of Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine. The vaccine, named Covovax, is produced by the Serum Institute of India and is part of the COVAX facility portfolio.

WHO Issues Emergency Use Listing to Novavax-Serum Institute's COVID-19 Vaccine

The authorization could pave the way for the vaccine to be distributed in more countries.

WHO Grants Novavax Covid Vaccine Emergency Use Approval As Omicron Fears Deepen

LOS ANGELES, Dec. 17, 2021 /PRNewswire/ --  Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Novavax, Inc. ("Novavax" or the "Company") (NASDAQ: NVAX). Class Period: March 2, 2021 – October 19, 2021 Lead Plaintiff Deadline: January 11, 2022 If you wish to serve as lead plaintiff of the Novavax lawsuit, you can submit your contact information at www.glancylaw.com/cases/novavax-inc/.

NVAX Investors Have Opportunity to Lead Novavax, Inc. Securities Fraud Lawsuit

Novavax Inc. (NASDAQ:NVAX) shares were trading higher Friday after the World Health Organization issued emergency use listing for its NVX-CoV2373 COVID-19 vaccine. The stock is trading higher and saw a push toward a resistance level in the pattern in which it trades.

Novavax Stock Pushes Higher In A Pattern: Technical Analysis

The vaccine maker and the Serum Institute of India were issued an emergency use authorization for their Covid-19 vaccine by the World Health Organization.

Novavax Covid Vaccine Gets Emergency-Use Approval From WHO

The World Health Organization granted Emergency Use Listing to its COVID-19 vaccine.

Why Novavax Stock Is Jumping Again Today

Today, the WHO approved emergency use listing for Novavax's vaccine, Covovax. NVAX stock is popping today as a result.

NVAX Stock Pops as the WHO Grants Novavax's Vaccine Emergency Use. 8 Things to Know.

First EUL granted by WHO for a protein-based COVID-19 vaccine EUL vaccine manufactured and marketed by SII as COVOVAX™ WHO EUL for Nuvaxovid™ currently under assessment; will be completed following European Medicines Agency (EMA) review GAITHERSBURG, Md. and PUNE, India, Dec. 17, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt.

Novavax and Serum Institute of India Announce World Health Organization Grants Emergency Use Listing for NVX-CoV2373 COVID-19 Vaccine

AbbVie

Calliditas Therapeutics AB

Valneva SE

Should investors be treating these top biotech stocks as top picks in the stock market now?

News for Novavax Stock (NVAX)